Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).

In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: ##STR00001##
wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.

In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: ##STR00001##
wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.

Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.

Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.

A cerium oxide nanoparticle is produced by adding an oxidant to a solution comprising a boron compound represented by formula (I) and a cerium (III) ion:

BR.sub.n(OR′).sub.3-n  (I)

wherein n represents an integer of 0 to 2, R represents any of an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and R′ represents any of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and when a plurality of Rs or of R's are present, the plurality of Rs or of R's are optionally the same or different.

The present technology relates generally to a method of manufacture comprising: preparing at a first temperature a non-supersaturated solution comprising a micelle forming block copolymer and a drug in a polyethylene glycol (PEG) solvent; and diluting the non-supersaturated solution with water at a second temperature to form an aqueous solution comprising drug-loaded micelles without crystallization of the PEG block(s) of the block copolymer; wherein the block copolymer comprises at least one PEG block and a second biocompatible polymer block that is not PEG, the drug has a water solubility of about or less than 10 mg/mL at 25° C., and the second temperature is lower than the first temperature, but does not allow the cooled solution to become supersaturated.

The present technology relates generally to a method of manufacture comprising: preparing at a first temperature a non-supersaturated solution comprising a micelle forming block copolymer and a drug in a polyethylene glycol (PEG) solvent; and diluting the non-supersaturated solution with water at a second temperature to form an aqueous solution comprising drug-loaded micelles without crystallization of the PEG block(s) of the block copolymer; wherein the block copolymer comprises at least one PEG block and a second biocompatible polymer block that is not PEG, the drug has a water solubility of about or less than 10 mg/mL at 25° C., and the second temperature is lower than the first temperature, but does not allow the cooled solution to become supersaturated.

An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.